Missed opportunities for sexually transmitted infections testing for HIV pre-exposure prophylaxis users: a systematic review.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
02 2021
Historique:
received: 16 07 2020
revised: 09 01 2021
accepted: 26 01 2021
entrez: 19 2 2021
pubmed: 20 2 2021
medline: 18 9 2021
Statut: ppublish

Résumé

Given the synergistic relationship between HIV and sexually transmitted infections (STI), the integration of services has the potential to reduce the incidence of both HIV and STIs. We explored the extent to which STI testing has been offered within HIV pre-exposure prophylaxis (PrEP) programmes worldwide. We conducted a systematic review of PrEP programmes implementing STI testing services in nine databases. We approached PrEP implementers for additional unpublished data and implementation details. Descriptive statistics were used to present the characteristics of STI testing within PrEP programmes. Content analysis of the input from PrEP implementers was conducted to summarize the barriers to and facilitators of STI testing. Of 9,161 citations, 91 studies conducted in 32 countries were included: 69% from high-income countries (HICs) and 64% from programmes targeting men who have sex with men (MSM) and transgender women (TGW) only. The majority of programmes (70%, 64/91) conducted STI testing before the initiation of PrEP. The most common STIs tested were gonorrhoea (86%, 78/91), chlamydia (84%, 76/91) and syphilis (84%, 76/91). The majority provided STI testing at three-month intervals (70%, 53/76, for syphilis; 70% 53/78, for chlamydia; 68%, 53/78, for gonorrhoea). Relative to low- and middle-income countries (LMICs), a higher proportion of PrEP programmes in HICs offered testing for gonorrhoea (92% vs. 71%, p < 0.05), chlamydia (92% vs. 64%, p < 0.01), syphilis (87% vs. 75%, p < 0.05), hepatitis A (18% vs. 4%, p < 0.05) and hepatitis C (43% vs. 21%, p < 0.05); offered testing for a higher number of STIs (mean 3.75 vs. 3.04, p < 0.05); and offered triple (throat, genital/urine and anorectal) anatomical site screening (54% vs. 18%, p < 0.001). Common implementation challenges included costs, access to STI diagnostics, programme logistics of integrating STI testing into PrEP delivery models and lack of capacity building for staff involved in PrEP provision. Significant gaps and challenges remain in the provision of STI testing services within HIV PrEP programmes. We recommend more active integration of STI testing and management into PrEP programmes, supported by standardized practice guidelines, staff capacity building training and adequate funding. This could lead to improved sexual health and HIV outcomes in key populations.

Identifiants

pubmed: 33605081
doi: 10.1002/jia2.25673
pmc: PMC7893146
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25673

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

PLoS One. 2018 Dec 3;13(12):e0208107
pubmed: 30507962
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Bull World Health Organ. 2019 Aug 1;97(8):548-562P
pubmed: 31384073
Lancet HIV. 2018 Nov;5(11):e629-e637
pubmed: 30343026
AIDS. 2016 Sep 10;30(14):2251-2
pubmed: 27314179
Obstet Gynecol. 2018 Sep;132(3):687-691
pubmed: 30095764
JAMA Netw Open. 2019 Dec 2;2(12):e1917134
pubmed: 31825501
Clin Infect Dis. 2017 Aug 1;65(3):389-395
pubmed: 28419198
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
Lancet HIV. 2017 Nov;4(11):e482-e483
pubmed: 29066095
Sex Transm Infect. 2017 Dec;93(S4):S69-S80
pubmed: 29223965
Emerg Infect Dis. 2020 Mar;26(3):505-515
pubmed: 32091356
Clin Infect Dis. 2018 Aug 16;67(5):676-686
pubmed: 29509889
J Int AIDS Soc. 2021 Feb;24(2):e25673
pubmed: 33605081
Sex Health. 2018 Nov;15(6):481-484
pubmed: 30496716
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
Clin Infect Dis. 2017 Sep 1;65(5):712-718
pubmed: 28505240
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103

Auteurs

Jason J Ong (JJ)

London School of Hygiene and Tropical Medicine, London, UK.
Monash University, Melbourne, Australia.

Hongyun Fu (H)

Eastern Virginia Medical School, Norfolk, VA, USA.

Rachel C Baggaley (RC)

World Health Organization, Geneva, Switzerland.

Teodora E Wi (TE)

World Health Organization, Geneva, Switzerland.

Joseph D Tucker (JD)

London School of Hygiene and Tropical Medicine, London, UK.
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

M Kumi Smith (MK)

University of Minnesota, Minneapolis, MN, USA.

Sabrina Rafael (S)

London School of Hygiene and Tropical Medicine, London, UK.

Jane Falconer (J)

London School of Hygiene and Tropical Medicine, London, UK.

Fern Terris-Prestholt (F)

London School of Hygiene and Tropical Medicine, London, UK.

Ioannis Mameletzis (I)

World Health Organization, Geneva, Switzerland.

Phillipe Mayaud (P)

London School of Hygiene and Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH